VS-5584

· Verastem, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for VS-5584, covering 2017-01-27 to 2017-01-30. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma [Phase 1]

See pricing